The Next Cancer-Blood-Test Winner May Be the Company That Helps Hospitals Prioritise Investigations
- For
- Diagnostic developers, NHS procurement and service planners, and healthcare investors.
- Where
- English primary-care trial; global listed names are research comparisons, not equivalent clinical populations.
- What it means
England is testing whether blood tests can improve urgent cancer referrals for symptomatic patients alongside GP judgement.
- Why it matters
Better decisions could improve access, but a referral that rules out cancer is not automatically unnecessary.
- What to do
Compare missed cancers, diagnosis times, total investigations, patient outcomes and full pathway costs before procurement or investment.
- What we don't know
Safety, clinical benefit, savings and nationwide purchasing remain unproven. Natera’s exact trial assay needs clarification; negative results must not override indicated investigation.
- Urgency
- 5/1,000
- A new trial makes referral-support diagnostics timely to investigate. Clinical decisions should follow established care, not this investment hypothesis.
First published